ATE173503T1 - Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma - Google Patents

Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma

Info

Publication number
ATE173503T1
ATE173503T1 AT92917640T AT92917640T ATE173503T1 AT E173503 T1 ATE173503 T1 AT E173503T1 AT 92917640 T AT92917640 T AT 92917640T AT 92917640 T AT92917640 T AT 92917640T AT E173503 T1 ATE173503 T1 AT E173503T1
Authority
AT
Austria
Prior art keywords
elam
asthma
antibodies
treatment
endothelial cells
Prior art date
Application number
AT92917640T
Other languages
English (en)
Inventor
Robert H Gundel
Craig D Wegner
L Gordon Letts
C Wayne Smith
Original Assignee
Boehringer Ingelheim Pharma
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Baylor College Medicine filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE173503T1 publication Critical patent/ATE173503T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
AT92917640T 1991-07-31 1992-07-31 Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma ATE173503T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73863391A 1991-07-31 1991-07-31

Publications (1)

Publication Number Publication Date
ATE173503T1 true ATE173503T1 (de) 1998-12-15

Family

ID=24968819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92917640T ATE173503T1 (de) 1991-07-31 1992-07-31 Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma

Country Status (12)

Country Link
US (1) US5843441A (de)
EP (1) EP0551501B1 (de)
JP (1) JPH06502195A (de)
KR (1) KR100252621B1 (de)
AT (1) ATE173503T1 (de)
AU (1) AU663332B2 (de)
CA (1) CA2083273A1 (de)
DE (1) DE69227618T2 (de)
DK (1) DK0551501T3 (de)
ES (1) ES2123570T3 (de)
HU (1) HU215549B (de)
WO (1) WO1993002702A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041636A1 (en) * 1995-06-13 1996-12-27 The Nisshin Oil Mills, Ltd. Antiasthmatic agent
US6008203A (en) * 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers
US7247302B1 (en) * 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
CA2446828C (en) * 2001-05-08 2011-01-04 Blanchette Rockefeller Neurosciences Institute Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
BR112022014417A2 (pt) * 2020-01-24 2022-09-13 Pfizer Anticorpos anti-e-selectina, composições e métodos de uso

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005539A1 (en) * 1988-11-14 1990-05-31 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
DE69000248T2 (de) * 1989-03-09 1993-01-07 Boehringer Ingelheim Pharma Verwendung von interzellularen adhaesions-molekuelen und deren bindungsliganden bei der behandlung von asthma.
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands

Also Published As

Publication number Publication date
EP0551501B1 (de) 1998-11-18
ES2123570T3 (es) 1999-01-16
HUT69623A (en) 1995-09-28
DE69227618D1 (de) 1998-12-24
EP0551501A4 (en) 1993-09-22
US5843441A (en) 1998-12-01
AU2441092A (en) 1993-03-02
WO1993002702A1 (en) 1993-02-18
DK0551501T3 (da) 1999-08-02
JPH06502195A (ja) 1994-03-10
HU9300928D0 (en) 1993-06-28
DE69227618T2 (de) 1999-05-06
CA2083273A1 (en) 1993-02-01
HU215549B (hu) 1999-01-28
KR930702025A (ko) 1993-09-08
KR100252621B1 (ko) 2000-09-01
EP0551501A1 (de) 1993-07-21
AU663332B2 (en) 1995-10-05

Similar Documents

Publication Publication Date Title
EP1064308A4 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE69628912D1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
ATE163195T1 (de) Lösliche liganden für cd40
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
DE58906363D1 (de) Verfahren zur Überführung von festen, weitgehend wasserfreien Abfallstoffen in Glasform sowie Vorrichtung zur Durchführung des Verfahrens.
DE68900949D1 (de) Verfahren zur trennung von wasserstoffbehandlungs-ausfluessen.
DE69407272D1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
DE69013880D1 (de) Verfahren und Vorrichtung zur Behandlung von Absorptionssuspensionen, die Flugasche beinhalten.
DE68913205D1 (de) Verfahren zum aufbewahren und sammeln von müll, sowie müllbehälter zur durchführung des verfahrens.
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
ATE173503T1 (de) Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE69216600D1 (de) Synthetisches CDw52(CAMPATH-1) Peptidantigen
EP0711159A4 (de) Verfahren und zusammensetzungen zur behandlung von asthma, arthereosklerose und entzuendlichen erkrankungen unter verwendung von optisch reinem (-)-zilenton
DE69923778D1 (de) Verfahren und anlagen zum behandeln von abwässern aus kleinen gemeinschaften
ATE294250T1 (de) Vorrichtung zur filtration von und zugabe von kornfeinungsmittel zu metallschmelzen
DE69111324D1 (de) Vorrichtung zur Behandlung oder Trennung von Gasen.
DE69610411D1 (de) Verfahren zur trennung von p-xylol, das eine vorbehandlung durch selektive hydrierung und eine behandlung mit aktiver erde umfasst
ATE155481T1 (de) Verfahren zur reinigung von streptolysin 0, intaktes streptolysin 0 erhältlich nach diesem verfahren und seine verwendung
DE59611293D1 (de) Protein mit dnase-aktivität
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee